Design Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Design Therapeutics, Inc. (DSGN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $9.20 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.13, a 50.66% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.06, a 137.65% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.55, a 67.72% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $7.90, a 38.90% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.74, a 104.27% increase from fiscal 2024.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.81, a 46.58% decline from fiscal 2023.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.26, a 61.04% decline from fiscal 2022.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $13.50, a 13.46% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.20 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $9.13 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | $5.74 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $5.74 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $5.80 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $6.06 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $2.81 10-K · filed 2025-03-10 | |||
| 2024-09-30 | $2.61 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $2.61 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $2.55 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $5.26 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $5.49 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $7.76 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $7.90 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $13.50 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $13.45 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $12.93 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $12.93 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $15.60 10-K · filed 2023-03-14 | |||
| 2020-12-31 | $0.93 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |